Rystiggo Injection, Solution
Product Images NDC 50474-982

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Rystiggo (NDC 50474-982). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rystiggo 01)

A line graph showing mean change from baseline (CFB) in MG-ADL scores over time (days) comparing Rystiggo subcutaneous injection at approximately 7 mg/kg and 10 mg/kg doses versus placebo. The graph contains separate phases labeled Treatment and Observation. Rystiggo groups show greater score reductions during Treatment, with gradual increases during Observation, while placebo remains relatively stable. Data points include error bars; patient counts per group are shown below the x-axis.*

FDA Label Image

Principal Display Panel (2 mL Vial Carton)

Carton label for RYSTIGGO (rozanolixizumab-noli) injection, solution for subcutaneous use, containing 280 mg per 2 mL (140 mg/mL). The label states it is a single-dose vial to be administered by a healthcare provider only. Storage instructions advise refrigeration and light protection. The product is labeled by UCB, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.